These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 38662832)
1. Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells. Offensperger F; Tin G; Duran-Frigola M; Hahn E; Dobner S; Ende CWA; Strohbach JW; Rukavina A; Brennsteiner V; Ogilvie K; Marella N; Kladnik K; Ciuffa R; Majmudar JD; Field SD; Bensimon A; Ferrari L; Ferrada E; Ng A; Zhang Z; Degliesposti G; Boeszoermenyi A; Martens S; Stanton R; Müller AC; Hannich JT; Hepworth D; Superti-Furga G; Kubicek S; Schenone M; Winter GE Science; 2024 Apr; 384(6694):eadk5864. PubMed ID: 38662832 [TBL] [Abstract][Full Text] [Related]
2. Ligand and Target Discovery by Fragment-Based Screening in Human Cells. Parker CG; Galmozzi A; Wang Y; Correia BE; Sasaki K; Joslyn CM; Kim AS; Cavallaro CL; Lawrence RM; Johnson SR; Narvaiza I; Saez E; Cravatt BF Cell; 2017 Jan; 168(3):527-541.e29. PubMed ID: 28111073 [TBL] [Abstract][Full Text] [Related]
3. Fragment-Based Covalent Ligand Screening Enables Rapid Discovery of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP. Johansson H; Isabella Tsai YC; Fantom K; Chung CW; Kümper S; Martino L; Thomas DA; Eberl HC; Muelbaier M; House D; Rittinger K J Am Chem Soc; 2019 Feb; 141(6):2703-2712. PubMed ID: 30657686 [TBL] [Abstract][Full Text] [Related]
4. 'Design, synthesis, and strategic use of small chemical probes toward identification of novel targets for drug development'. Castaldi MP; Hendricks JA; Zhang AX Curr Opin Chem Biol; 2020 Jun; 56():91-97. PubMed ID: 32375076 [TBL] [Abstract][Full Text] [Related]
5. Expanding chemogenomic space using chemoproteomics. Jones LH Bioorg Med Chem; 2019 Aug; 27(15):3451-3453. PubMed ID: 31221609 [TBL] [Abstract][Full Text] [Related]
8. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications. Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647 [TBL] [Abstract][Full Text] [Related]
9. Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs. Wang Y; Dix MM; Bianco G; Remsberg JR; Lee HY; Kalocsay M; Gygi SP; Forli S; Vite G; Lawrence RM; Parker CG; Cravatt BF Nat Chem; 2019 Dec; 11(12):1113-1123. PubMed ID: 31659311 [TBL] [Abstract][Full Text] [Related]
10. Emerging strategies for prospective discovery of molecular glue degraders. Wang B; Cao S; Zheng N Curr Opin Struct Biol; 2024 Jun; 86():102811. PubMed ID: 38598983 [TBL] [Abstract][Full Text] [Related]
11. [The application of small molecule bioactive probes in the identification of cellular targets]. Zhang J; Zhou HC Yao Xue Xue Bao; 2012 Mar; 47(3):299-306. PubMed ID: 22645752 [TBL] [Abstract][Full Text] [Related]
12. Discovery of small molecules targeting the tandem tudor domain of the epigenetic factor UHRF1 using fragment-based ligand discovery. Chang L; Campbell J; Raji IO; Guduru SKR; Kandel P; Nguyen M; Liu S; Tran K; Venugopal NK; Taylor BC; Holt MV; Young NL; Samuel ELG; Jain P; Santini C; Sankaran B; MacKenzie KR; Young DW Sci Rep; 2021 Jan; 11(1):1121. PubMed ID: 33441849 [TBL] [Abstract][Full Text] [Related]
14. The Vital Role of Proteomics in Characterizing Novel Protein Degraders. Zhang AX; Cassidy K; Dahl G; Moreau K; Pachl F; Zuhl AM SLAS Discov; 2021 Apr; 26(4):518-523. PubMed ID: 33615886 [TBL] [Abstract][Full Text] [Related]
15. The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway. De Cesare V; Johnson C; Barlow V; Hastie J; Knebel A; Trost M Cell Chem Biol; 2018 Sep; 25(9):1117-1127.e4. PubMed ID: 30017913 [TBL] [Abstract][Full Text] [Related]
16. Chemical proteomics and its impact on the drug discovery process. Miao Q; Zhang CC; Kast J Expert Rev Proteomics; 2012 Jun; 9(3):281-91. PubMed ID: 22809207 [TBL] [Abstract][Full Text] [Related]
17. Covalent fragment-based drug discovery for target tractability. McCarthy WJ; van der Zouwen AJ; Bush JT; Rittinger K Curr Opin Struct Biol; 2024 Jun; 86():102809. PubMed ID: 38554479 [TBL] [Abstract][Full Text] [Related]
18. High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics. Simard JR; Lee L; Vieux E; Improgo R; Tieu T; Phillips AJ; Fisher SL; Pollock RM; Park E SLAS Discov; 2021 Apr; 26(4):503-517. PubMed ID: 33430712 [TBL] [Abstract][Full Text] [Related]